173 related articles for article (PubMed ID: 34249782)
1. ATI-2307 Exhibits Equivalent Antifungal Activity in
Gerlach ES; Altamirano S; Yoder JM; Luggya TS; Akampurira A; Meya DB; Boulware DR; Rhein J; Nielsen K
Front Cell Infect Microbiol; 2021; 11():695240. PubMed ID: 34249782
[TBL] [Abstract][Full Text] [Related]
2. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
4. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
5. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
9. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
11. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
[TBL] [Abstract][Full Text] [Related]
12. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
15. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Nooney L; Matthews RC; Burnie JP
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
[TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
19. [Behaviour azole fungicide and fluconazole in Cryptococcus neoformans clinical and environmental isolates].
Drummond ED; Reimão JQ; Dias AL; de Siqueira AM
Rev Soc Bras Med Trop; 2007; 40(2):209-11. PubMed ID: 17568890
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]